Stay updated on Ipilimumab Nivolumab in Mucosal Melanoma Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab Nivolumab in Mucosal Melanoma Clinical Trial page.

Latest updates to the Ipilimumab Nivolumab in Mucosal Melanoma Clinical Trial page
- Check6 days agoChange DetectedThe study record for the phase II mucosal melanoma trial is displayed, including its ipilimumab and nivolumab regimen, participant criteria, study locations, and record information.SummaryDifference54%

- Check13 days agoChange DetectedThe site revision label changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide NIH notice explains the transition from “Artificial Intelligence” to “Super Intelligence,” and the site revision advances from v3.7.1 to v3.7.2. The study page continues to display a 403 error.SummaryDifference1%

- Check34 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check55 days agoChange DetectedThe Study Record page now shows a 403 Forbidden error instead of the usual study details, indicating an access issue rather than content changes.SummaryDifference19%

- Check62 days agoChange DetectedRevision labeled as v3.7.0 replaces the previous v3.6.6. This appears to be a maintenance version update without affecting the study information displayed on the page.SummaryDifference0.1%

Stay in the know with updates to Ipilimumab Nivolumab in Mucosal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab in Mucosal Melanoma Clinical Trial page.